Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects-Reference-Cited by-同舟云学术

Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects

Published:2022-11 Issue: Volume:309 Page:120984
ISSN:0024-3205
Container-title:Life Sciences
language:en
Short-container-title:Life Sciences

Author:

Hashemi Mehrdad,Mirzaei Sepideh,Barati Maryamsadat,Hejazi Elahe Sadat,Kakavand Amirabbas,Entezari Maliheh,Salimimoghadam Shokooh,Kalbasi Alireza,Rashidi Mohsen,Taheriazam Afshin,Sethi Gautam

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference329 articles.

1. 10-year mortality pattern among cancer patients in Lagos State University Teaching Hospital, Ikeja, Lagos;Fatiregun;Front. Oncol.,2020

2. The synergistic antitumor effects of all-trans retinoic acid and C-phycocyanin on the lung cancer A549 cells in vitro and in vivo;Li;Eur. J. Pharmacol.,2015

3. Cancer statistics, 2015;Siegel;CA Cancer J. Clin.,2015

4. Long non-coding RNAs as new players in bladder cancer: lessons from pre-clinical and clinical studies;Mirzaei;Life Sci.,2021

5. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response;Ashrafizadeh;J. Exp. Clin. Cancer Res.,2022

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long non-coding RNA HOTAIR: A biomarker and therapeutic target in urological tumors;Pathology - Research and Practice;2024-10

2. Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view;Functional & Integrative Genomics;2024-09-02

3. Biological functions and therapeutic potential of CKS2 in human cancer;Frontiers in Oncology;2024-08-12

4. Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes;Journal of Clinical Medicine;2024-07-14

5. Biological functions and therapeutic potential of SRY related high mobility group box 5 in human cancer;Frontiers in Oncology;2024-05-21